medicalxpress - Modern medicine has made significant advances in cancer treatments over the decades. But all cancer therapies still face one critical challenge: how to target cancers without damaging healthy cells.
AI Summary: Researchers engineered bacteria that selectively attack and consume tumor tissue in preclinical models, demonstrating promising tumor control and a novel mechanism to deliver anti‑cancer effects. Significant questions remain about safety, immune responses and delivery in humans, so while the “bacteria that eat cancer” headline is delightful, translation to patients will require cautious, rigorous steps.
Daraxonrasib shows encouraging activity in NRAS-driven melanoma patients / 2 days
Rogaratinib shows activity in SDH‑deficient GIST phase 2 trial / 7 wks
Genetic clues explain tagraxofusp resistance in rare leukemia (BPDCN) / 9 days
Adjuvant selpercatinib sharply cuts recurrence in RET‑fusion lung cancer / 6 wks
CRISPR CD33‑deleted allogeneic transplant shows early AML promise / 2 months
Single‑cycle pembrolizumab yields striking responses in dMMR colon cancer / 2 months
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 16 days
StackHealth RSS


StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.